

Susan Tsai, Mhs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9648393/publications.pdf>

Version: 2024-02-01

122
papers

2,999
citations

186265

28
h-index

182427

51
g-index

124
all docs

124
docs citations

124
times ranked

5017
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. <i>BMC Cancer</i> , 2018, 18, 335.	2.6	271
2	Plasma extracellular RNA profiles in healthy and cancer patients. <i>Scientific Reports</i> , 2016, 6, 19413.	3.3	224
3	Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?. <i>Oncologist</i> , 2014, 19, 266-274.	3.7	183
4	Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. <i>Annals of Surgery</i> , 2020, 271, 740-747.	4.2	127
5	Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. <i>Surgery</i> , 2016, 159, 893-900.	1.9	114
6	A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer. <i>Npj Precision Oncology</i> , 2019, 3, 25.	5.4	98
7	Arterial resection at the time of pancreatectomy for cancer. <i>Surgery</i> , 2014, 155, 919-926.	1.9	94
8	Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer. <i>Cancer Research</i> , 2015, 75, 3314-3326.	0.9	89
9	Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. <i>Hpb</i> , 2017, 19, 659-666.	0.3	84
10	Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 3716-3723.	1.5	83
11	Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. <i>Frontiers in Oncology</i> , 2020, 10, 553.	2.8	74
12	CXCL12 Chemokine Expression Suppresses Human Pancreatic Cancer Growth and Metastasis. <i>PLoS ONE</i> , 2014, 9, e90400.	2.5	74
13	Importance of Lean Body Mass in the Oncologic Patient. <i>Nutrition in Clinical Practice</i> , 2012, 27, 593-598.	2.4	65
14	A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2018, 268, 610-619.	4.2	58
15	Pancreatic Cancer Cell Migration and Metastasis Is Regulated by Chemokine-Biased Agonism and Bioenergetic Signaling. <i>Cancer Research</i> , 2015, 75, 3529-3542.	0.9	56
16	Locally advanced pancreas cancer: Staging and goals of therapy. <i>Surgery</i> , 2018, 163, 1053-1062.	1.9	53
17	p38 ^β MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis. <i>Cancer Research</i> , 2020, 80, 3251-3264.	0.9	47
18	Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 41-46.	0.6	44

#	ARTICLE	IF	CITATIONS
19	Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1395-1403.	4.1	44
20	Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. <i>American Journal of Surgery</i> , 2021, 222, 10-17.	1.8	41
21	Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. <i>Surgery</i> , 2019, 166, 277-285.	1.9	40
22	Techniques of Vascular Resection and Reconstruction in Pancreatic Cancer. <i>Surgical Clinics of North America</i> , 2016, 96, 1351-1370.	1.5	39
23	Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls. <i>Lung Cancer</i> , 2015, 90, 78-84.	2.0	38
24	Improving Treatment Response Prediction for Chemoradiation Therapy of Pancreatic Cancer Using a Combination of Delta-Radiomics and the Clinical Biomarker CA19-9. <i>Frontiers in Oncology</i> , 2019, 9, 1464.	2.8	38
25	Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. <i>Surgery</i> , 2015, 158, 1545-1555.	1.9	36
26	Surgical resection versus ablation for hepatocellular carcinoma: a population-based analysis. <i>Hpb</i> , 2015, 17, 896-901.	0.3	34
27	Neoadjuvant therapy for localized pancreatic cancer: guiding principles. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 418-29.	1.4	32
28	Can response to treatment predict outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)? <i>Journal of Clinical Oncology</i> , 2016, 34, 443-443.	1.6	31
29	Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma. <i>Laboratory Investigation</i> , 2017, 97, 302-317.	3.7	30
30	Overall survival after resection of retroperitoneal sarcoma at academic cancer centers versus community cancer centers: An analysis of the National Cancer Data Base. <i>Surgery</i> , 2018, 163, 318-323.	1.9	29
31	Total Neoadjuvant Therapy for Operable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2246-2256.	1.5	29
32	Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival. <i>Annals of Surgical Oncology</i> , 2016, 23, 912-920.	1.5	28
33	The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients. <i>Journal of Surgical Oncology</i> , 2017, 116, 831-840.	1.7	27
34	EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 6135-6144.	7.0	26
35	Evolution of the Management of Resectable Pancreatic Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 772-778.	2.5	24
36	Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1793-1803.	1.7	24

#	ARTICLE	IF	CITATIONS
37	Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated?. <i>Journal of Surgical Oncology</i> , 2016, 114, 581-586.	1.7	23
38	Minimally invasive hepatectomy conversions: an analysis of risk factors and outcomes. <i>Hpb</i> , 2018, 20, 132-139.	0.3	23
39	Molecular and Genetic Markers in Appendiceal Mucinous Tumors: A Systematic Review. <i>Annals of Surgical Oncology</i> , 2020, 27, 85-97.	1.5	22
40	Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability. <i>Oncogene</i> , 2020, 39, 4257-4270.	5.9	22
41	External radiation or ablation for solitary hepatocellular carcinoma: A survival analysis of the SEER database. <i>Journal of Surgical Oncology</i> , 2017, 116, 307-312.	1.7	21
42	Development of a high risk pancreatic screening clinic using 3.0T MRI. <i>Familial Cancer</i> , 2018, 17, 101-111.	1.9	20
43	Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 460.	2.8	20
44	Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. <i>Journal of Oncology Practice</i> , 2016, 12, 915-923.	2.5	19
45	Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 548-558.	1.4	18
46	Two-Stage Hepatectomy for Bilateral Colorectal Liver Metastases: A Multi-institutional Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 1457-1465.	1.5	17
47	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3773-3777.	1.6	17
48	Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2016, 114, 291-295.	1.7	16
49	Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 985-997.	4.1	15
50	Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. <i>Surgery</i> , 2020, 168, 440-447.	1.9	15
51	Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. <i>Clinical Cancer Research</i> , 2021, 27, 226-236.	7.0	15
52	Distal splenorenal and mesocaval shunting at the time of pancreatectomy. <i>Surgery</i> , 2019, 165, 298-306.	1.9	14
53	Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 275, e229-e237.	4.2	14
54	RAS Mutation Status Confers Prognostic Relevance in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer. <i>Journal of Surgical Research</i> , 2019, 240, 130-135.	1.6	13

#	ARTICLE	IF	CITATIONS
55	Pancreatic ductal adenocarcinomas associated with intraductal papillary mucinous neoplasms (IPMNs) versus pseudo-IPMNs: relative frequency, clinicopathologic characteristics and differential diagnosis. <i>Modern Pathology</i> , 2022, 35, 96-105.	5.5	13
56	Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?. <i>Cancers</i> , 2021, 13, 5204.	3.7	13
57	Black Raspberries Suppress Colorectal Cancer by Enhancing Smad4 Expression in Colonic Epithelium and Natural Killer Cells. <i>Frontiers in Immunology</i> , 2020, 11, 570683.	4.8	12
58	Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis. <i>Abdominal Radiology</i> , 2018, 43, 351-363.	2.1	11
59	Black raspberries suppress pancreatic cancer through modulation of NKp46 ⁺ , CD8 ⁺ , and CD11b ⁺ immune cells. <i>Food Frontiers</i> , 2020, 1, 70-82.	7.4	11
60	Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. <i>Hpb</i> , 2015, 17, 1119-1123.	0.3	10
61	Elective Regional Therapy Treatment for Hepatic Adenoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 125-130.	1.5	10
62	Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers. <i>Hpb</i> , 2020, 22, 1675-1685.	0.3	10
63	Replaced gastroduodenal artery: Added benefit of the "artery first" approach during pancreaticoduodenectomy—a case report. <i>International Journal of Surgery Case Reports</i> , 2016, 23, 93-97.	0.6	9
64	Cancer-associated macrophage-like cells as prognostic indicators of overall survival in a variety of solid malignancies. <i>Journal of Clinical Oncology</i> , 2017, 35, 11503-11503.	1.6	9
65	The effect of prior upper abdominal surgery on outcomes after liver transplantation for hepatocellular carcinoma: An analysis of the database of the organ procurement transplant network. <i>Surgery</i> , 2018, 163, 1028-1034.	1.9	8
66	Effect of Donor Race-Matching on Overall Survival for African-American Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. <i>Journal of the American College of Surgeons</i> , 2019, 228, 245-254.	0.5	8
67	Neoadjuvant therapy for pancreatic cancer in patients older than age 75. <i>Journal of Clinical Oncology</i> , 2014, 32, 287-287.	1.6	8
68	Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 4515-4521.	1.5	7
69	Primary Liver Cancer: An NCDB Analysis of Overall Survival and Margins After Hepatectomy. <i>Annals of Surgical Oncology</i> , 2020, 27, 1156-1163.	1.5	7
70	Comparison of overall survival in gallbladder carcinoma at academic versus community cancer centers: An analysis of the National Cancer Data Base. <i>Journal of Surgical Oncology</i> , 2020, 122, 176-182.	1.7	7
71	Outcomes of palliative-intent surgery in retroperitoneal sarcoma—Results from the US Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2020, 121, 1140-1147.	1.7	7
72	Outcomes of Elderly Patients Undergoing Curative Resection for Retroperitoneal Sarcomas: Analysis From the US Sarcoma Collaborative. <i>Journal of Surgical Research</i> , 2019, 233, 154-162.	1.6	6

#	ARTICLE	IF	CITATIONS
73	Has Personalized Medicine for Pancreatic Cancer Arrived?. <i>Advances in Surgery</i> , 2019, 53, 103-115.	1.3	6
74	Molecular Characteristics of Biliary Tract and Primary Liver Tumors. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 685-693.	1.5	6
75	Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice?. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 235-242.	1.7	6
76	Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma. <i>Annals of Diagnostic Pathology</i> , 2020, 46, 151485.	1.3	6
77	Ablation approach for primary liver tumors: Perioperative outcomes. <i>Journal of Surgical Oncology</i> , 2018, 117, 1493-1499.	1.7	5
78	Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine + nab-paclitaxel (NabG).. <i>Journal of Clinical Oncology</i> , 2016, 34, 397-397.	1.6	5
79	Gallbladder carcinoma: An analysis of the national cancer data base to examine hispanic influence. <i>Journal of Surgical Oncology</i> , 2018, 117, 1664-1671.	1.7	4
80	Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level. <i>Frontiers in Oncology</i> , 2021, 11, 606820.	2.8	4
81	Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer—Medical college of Wisconsin perspective. <i>Journal of Surgical Oncology</i> , 2021, 123, 1405-1413.	1.7	4
82	A Novel Reconstruction Technique During Pancreaticoduodenectomy After Roux-En-Y Gastric Bypass: How I do It. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1186-1191.	1.7	3
83	Updates on the Management of Pancreatic Cancer. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, xvii-xviii.	1.5	3
84	Correlation of cancer-associated macrophage-like cells with systemic therapy and pathological stage in numerous malignancies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11095-11095.	1.6	3
85	A Serum-Induced Transcriptome and Serum Cytokine Signature Obtained at Diagnosis Correlates with the Development of Early Pancreatic Ductal Adenocarcinoma Metastasis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 680-689.	2.5	2
86	High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma. <i>Surgery</i> , 2020, 168, 760-767.	1.9	2
87	Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. <i>Surgery</i> , 2021, 169, 629-635.	1.9	2
88	Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. <i>Hpb</i> , 2020, 22, 1745-1752.	0.3	2
89	Low cytokeratin- and low EpCAM-expressing circulating tumor cells in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11046-11046.	1.6	2
90	Association of decline in serum Ca19-9 after neoadjuvant therapy with improved survival among borderline resectable pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15082-e15082.	1.6	2

#	ARTICLE	IF	CITATIONS
91	Can the sequence of chemotherapy regimens influence outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)?. <i>Journal of Clinical Oncology</i> , 2016, 34, 428-428.	1.6	2
92	Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 879-889.	5.9	2
93	Lessons learned from investigator-initiated clinical trials for localized pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2022, 125, 69-74.	1.7	2
94	MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in <i>KRAS</i> -mutated advanced pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16260-e16260.	1.6	2
95	Phase II clinical trial of biomarker-directed therapy for localized pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4147-TPS4147.	1.6	1
96	Reconstructing the tumor microenvironment to unlock therapeutic options in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 589-589.	1.6	1
97	Trading up: Balancing centralization and its trade-offs. <i>American Journal of Surgery</i> , 2022, , .	1.8	1
98	Palliative Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Is It Safe and Effective?. <i>Journal of Surgical Research</i> , 2022, 278, 31-38.	1.6	1
99	Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer?. <i>Practical Radiation Oncology</i> , 2017, 7, e449-e455.	2.1	0
100	Moving Toward a More Informed Approach to Risk Stratification of Patients: Comments on Seror et al. CT-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related HCC. <i>Annals of Surgical Oncology</i> , 2021, 28, 24-26.	1.5	0
101	Precision Medicine for Pancreatic Cancer. <i>Advances in Oncology</i> , 2021, 1, 63-71.	0.2	0
102	Current Controversies in Neoadjuvant Therapy for Pancreatic Cancer. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 657-671.	1.5	0
103	Does a common vascular origin confer similar prognosis to malignant tumors of the liver?. <i>Journal of Clinical Oncology</i> , 2012, 30, 186-186.	1.6	0
104	Are we justified in excluding combined hepatocellular-cholangiocarcinoma from transplantation?. <i>Journal of Clinical Oncology</i> , 2012, 30, 256-256.	1.6	0
105	Local control in resectable and borderline resectable pancreatic cancer (PCa) treated with preoperative chemoradiation using IMRT or chemotherapy alone.. <i>Journal of Clinical Oncology</i> , 2013, 31, 282-282.	1.6	0
106	Molecular profiling in gastric cancer: Examining potential targets for chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 131-131.	1.6	0
107	A pilot study identifying cancer-associated macrophage-like cells in the blood of cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22014-e22014.	1.6	0
108	Chemotherapy for surgically resected intrahepatic cholangiocarcinoma: Influence of lymph node status on treatment efficacy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 353-353.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Genetic screening for patients with pancreatic cancer: Frequency of high-risk mutations.. Journal of Clinical Oncology, 2015, 33, e12526-e12526.	1.6	0
110	Rapid immunohistochemical analysis of pancreatic cytology from endoscopic ultrasound-guided fine-needle aspirates: A prospective clinical trial.. Journal of Clinical Oncology, 2016, 34, 400-400.	1.6	0
111	Overall survival and resection margin after hepatectomy for intrahepatic cholangiocarcinoma at academic cancer centers versus community cancer centers.. Journal of Clinical Oncology, 2016, 34, 339-339.	1.6	0
112	Two-stage hepatectomy for colorectal liver metastases: A multi-institutional retrospective review.. Journal of Clinical Oncology, 2017, 35, 351-351.	1.6	0
113	Should functional renal scans be obtained prior to upper abdominal radiation for pancreatic cancer?. Journal of Clinical Oncology, 2017, 35, 442-442.	1.6	0
114	Does hepatectomy approach influence transfusion? An analysis of the National Surgical Quality Improvement Program database.. Journal of Clinical Oncology, 2017, 35, 447-447.	1.6	0
115	Minimally invasive hepatectomy conversions: An analysis of outcomes.. Journal of Clinical Oncology, 2017, 35, 430-430.	1.6	0
116	Impact of age on genomic alterations associated with pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, 282-282.	1.6	0
117	Prognostic value of positron emission tomography and preoperative CA19-9 in patients treated on a prospective phase II trial of neoadjuvant therapy and surgery.. Journal of Clinical Oncology, 2017, 35, e15766-e15766.	1.6	0
118	Targeting of the Histone 3 Lysine 9 Methyltransferase Pathway in Kras ^{ΔE6} -Induced Cell Growth and Pancreatic Cancer. FASEB Journal, 2018, 32, 826.11.	0.5	0
119	Abstract PO-055: Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer. , 2021, , .		0
120	Comprehensive genomic profiling (CGP) of fibrolamellar oncocytic hepatoma (FLO) and conventional hepatocellular carcinomas (HCC): An observational study.. Journal of Clinical Oncology, 2022, 40, 474-474.	1.6	0
121	Targeted therapy (TT) in patients with KRAS wildtype (WT) pancreatic ductal adenocarcinoma (PDAC) produces durable response.. Journal of Clinical Oncology, 2022, 40, 596-596.	1.6	0
122	Neoadjuvant radiation case volume and associated with margin-negative resection rates in patients with pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, e16281-e16281.	1.6	0